Spectrum Pharmaceutecals Inc (SPPI)

[realfast95]

Spectrum won't need to refile as CRL not given, says H.C. Wainwright 09:29 SPPI H.C. Wainwright analyst Edward White lowered the firm's price target on Spectrum Pharmaceuticals, to $12 from $13 and reiterates a Buy rating on the shares after the FDA deferred action on the Biologics License Application for Rolontis. This is not a Complete Response Letter but a deferral, so there is no need to refile, White tells investors in a research note. Due to COVID-19-related travel restriction issues, the FDA was unable to conduct the inspection during the current review cycle, says the analyst. White pushed out his launch expectations by six months and says this may prove to be conservative.

Read more at:
https://thefly.com/n.php?id=3181704